Plerixafor

This classification denotes a chemokine receptor antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S915P5499N. European Medicines Agency schedules Plerixafor in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB28849. Plerixafor generally arises in the molecular formula C28H54N8. The term PLERIXAFOR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55.) PLERIXAFOR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule plerixafor under HS 29339990 and SITC 51577. As of Q4 2014, PLERIXAFOR remains the US FDA Preferred Term for this commodity. Plerixafor bears US NLM identifiers UMLS ID C0257001 and NCI Concept Code C1777. SMILES: C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.